If you're considering a slice of Australia's diagnostic healthcare sector, you might be torn between Healius Ltd (ASX: HLS) and Australian Clinical Labs Ltd (ASX: ACL) shares. Both companies are big names in pathology, with nationwide reach and established reputations. But their fundamentals, dividends, and recent share price momentum tell very different stories. Let's dive into what really sets these two healthcare stocks apart.

The case for Healius

Healius is one of Australia's largest pathology service providers, operating under well-known brands like Laverty, Dorevitch, and QML Pathology. Healius ran around 2,000 collection sites and close to 100 labs across the country. In May 2025, Healius sold its Lumus Imaging business and now focuses on pathology and its bioanalytical laboratory arm, Agilex Biolabs.

Looking at current fundamentals, three points really stand out:

• The share price has been hammered this year, with a -52.5% year-to-date return.
• Healius's P/E ratio is 55.56, with an earnings per share of -0.563. (Note: Healius's reported P/E ratio may be based on a different earnings measure than the EPS figure shown, which is why they may appear inconsistent.)
• Dividend yield is currently 0.00%. Despite a long history of fully franked payouts, the last special dividend was paid in May 2025, and before that, ordinary dividends dried up after 2022.

So while Healius is a large, established player with an extensive network, it's struggling for profitability and income at the moment.

The case for Australian Clinical Labs

Australian Clinical Labs is another leading pathology player, with a strong footprint across nearly all states and territories (excluding Tasmania). The company operates more than 75 laboratories and 1,300 collection centres, handling over 12 million episodes a year. ACL is also a significant provider to both private and public hospitals, and increasingly active in specialised screenings and commercial testing.

Here are a few of the most notable fundamentals right now:

• Year-to-date return is a healthy 8.4%—a far cry from Healius's collapse.
• The P/E ratio is 23.11, backed by positive earnings per share of 0.141.
• Dividend yield is 4.56%, with 100% franking. ACL has delivered regular, fully franked dividends; the latest was 9.25 cents per share in September 2026.

Overall, ACL is profitable, growing, and paying out a solid stream of income.

Valuation comparison

Here's how the two companies stack up on key numbers:

While both companies offer fully franked dividends, only ACL is currently paying and yielding above 4%. Healius has lost significant ground—both in share price and earnings.

Recent share price momentum

Comparing recent share price performance up to 1 October 2026:

• Healius closed at $0.42 on 1 October 2026, down 2.3% on the day and showing steep declines so far in 2026. Year to date, Healius is down 52.5%.
• Australian Clinical Labs closed at $2.76 on 1 October 2026, falling 3.2% that day, but overall in positive territory for 2026 with an 8.4% gain year to date.

Both shares dipped on the last trading day, but their trajectories are worlds apart this year. Healius has been in steep decline; ACL has outperformed and delivered positive momentum.

Which is the better buy?

If I had to choose between Healius and Australian Clinical Labs today, my pick would be clear: Australian Clinical Labs. The company is profitable, offers a solid fully franked dividend yield, and has delivered meaningful share price growth this year. Meanwhile, Healius is battling negative earnings, has halted regular dividends, and has seen its market cap and share price tumble by more than half in 2026. ACL's lower P/E ratio (compared to Healius) also suggests investors aren't paying as much for each dollar of earnings, at least within the context of these two healthcare stocks. While both serve a vital role in Australian pathology and may benefit from long-term healthcare trends, only ACL currently pairs business quality with real income and positive momentum. That's where I'd be leaning with my investment dollars today.

The post Healius vs Australian Clinical Labs: Which ASX pathology share wins? appeared first on The Motley Fool Australia.

However, the market has fallen into the red over 12 months, down 0.6%, amid rising oil prices and interest rates.

The Reserve Bank of Australia (RBA) lifted the official cash rate from 4.35% to 4.6% yesterday.

Experts say another rate rise may be required in November to combat persistently high inflation.

Inflation rose from 3.5% over the 12 months to July to 4% last month, according to data released today.

Amid the market weakness, brokers have raised their ratings on several ASX shares this week.

Let's see a sample. 

Capricorn Metals Ltd (ASX: CMM)

The Capricorn Metals share price is $15.22, up 1.9% today.

Over the past month, this ASX 200 gold share has fallen 8%.

Bell Potter upgraded Capricorn Metals shares to a buy rating this week.

The broker raised its 12-month price target from $18.05 to $18.10.

This implies a potential 19% upside ahead.

Evolution Mining Ltd (ASX: EVN)

The Evolution Mining share price is $13.40, up 1% today.

Over the past month, this ASX 200 mining share has fallen 10%.

UBS upgraded Evolution shares to a buy call this week.

The broker increased its 12-month price target from $15.20 to $16.

This suggests a potential 19% gain ahead.

REA Group Ltd (ASX: REA)

The REA share price is $156.16, up 4.9% today.

Over the past month, this ASX 200 communications share has dropped 12%.

Bell Potter upgraded REA to a hold recommendation with a price target of $148.

This suggests a potential 5% downside ahead.

Healius Ltd (ASX: HLS)

The Healius share price is 42 cents, up 1.7% today.

Over the past month, this ASX 200 healthcare share has fallen 2%.

RBC Capital upgraded Healius shares to a hold rating with a 12-month price target of 42 cents.

This implies the stock is fully valued.

Alliance Aviation Services Ltd (ASX: AQZ)

The Alliance Aviation Services share price is 54 cents, up 6.9% today.

Over the past month, this ASX industrials share has fallen 18%.

Morgans upgraded Alliance Aviation Services shares to a buy rating on Monday.

The broker has a 12-month price target of 85 cents.

This indicates potential capital gains of 57% over the next year. 

Pinnacle Investment Management Group Ltd (ASX: PNI)

Pinnacle Investment Management shares are $13.30 apiece, down 4.7% today.

Over the past month, this ASX 200 financial share has declined 21%.

UBS upgraded the stock to a buy rating but reduced its price target from $18 to $17.

This suggest a potential 28% upside ahead.

The post 6 ASX shares upgraded by experts amid a weak market  appeared first on The Motley Fool Australia.

Among the 11 market sectors, the technology sector is in the lead today, up 2.3%.

The energy sector is the laggard, down 0.9%. 

Let's check out some new ratings on ASX shares today.

Netwealth Ltd (ASX: NWL)

The Netwealth share price is $19.09, up 1.4% today and down 38% over 12 months. 

Dylan Evans from Catapult Wealth has a buy rating on this ASX financial share. 

Evans said (courtesy The Bull): 

The company's full year 2026 results continued to deliver strong growth, with the platform's funds under administration increasing 20.3 per cent to $135.7 billion and earnings per share growing 16 per cent to 55.2 cents.

Despite these strong results, the share price has fallen significantly, most likely and partially in response to a compensation payout of about $101 million to members in the collapsed First Guardian Master Fund.

Share price weakness presents an opportunity, as Netwealth still holds a net cash position and is poised to generate strong revenue growth moving forward.

Healius Ltd (ASX: HLS)

The Healius share price is steady at 38 cents, down 53% over 12 months. 

Ord Minnett has a hold rating on this ASX healthcare share. 

In a new note, the broker said: 

Revenues rose 2% to $1.4 billion, in-line with consensus, while underlying earnings before interest, tax, depreciation and amortisation (EBITDA) grew 8% to $259 million, 1% shy of consensus. 

The FY26 EBIT margin of 1.8% was below consensus expectations of 2.0% reflecting the burden of a largely fixed-cost operating base.

Management has made progress in controlling costs, especially labour, but will need to do more if it is to offset headwinds from continued weak volumes and the Fair Work Commission's (FWC) gender-based undervaluation decision on wages.

We increase interest cost assumptions which lowers our earnings estimates, and we do not see HLS returning to profitability until FY28.

Reflecting the earnings downgrades, the target price has been reduced from $0.56 to $0.49.

Tabcorp Holdings Ltd (ASX: TAH)

The Tabcorp share price is 96 cents, up 4.4% today and down 3% over 12 months. 

Evans has a sell rating on this ASX consumer discretionary share. 

The analyst said: 

The company generated group revenue of $2.636 billion in full year 2026, up 0.8 per cent on the prior corresponding period. Group EBITDA of $431.7 million was up 10.3 per cent.

In our view, a major challenge for Tabcorp is the highly competitive gambling industry and the underlying trend towards digital wagering amid the risk of potentially tighter regulations.

The company expects domestic wagering turnover growth in fiscal year 2027 to be broadly consistent with fiscal year 2026, excluding the FIFA World Cup.

The shares have fallen from $1.17 on May 1 to trade at 90 cents on September 17. Other stocks appeal more at this stage of the cycle.

The post Buy, hold, sell: Netwealth, Tabcorp, Healius shares appeared first on The Motley Fool Australia.

All 11 market sectors of the ASX 200 are in the green today.

Healthcare leads the pack, up 1.1%, extending its impressive recent rebound.

ARB Corporation Ltd (ASX: ARB) is the fastest riser of the ASX 200 today, up 18% on its FY26 report.

Meanwhile, Morgans has issued some new notes on three ASX shares.

They include BHP Group Ltd (ASX: BHP) shares, which hit a new all-time high today.

Let's take a look.

Judo Capital Holdings Ltd (ASX: JDO)

The Judo Capital share price is $1.03, up 6.4% today and down 42% over 12 months. 

Judo Capital shares are the fourth fastest riser on the local bourse despite no significant announcements today.

Morgans has a buy rating on this ASX bank share after its FY26 results.

The broker said: 

FY26 PBT landed towards the top end of the revised guidance range and FY27 guidance was reaffirmed offering strong earnings growth.

EPS forecasts moderated 2-6%.

The broker shaved its 12-month price target from $1.47 to $1.42.

This suggests a potential 40% upside ahead.

Healius Ltd (ASX: HLS)

The Healius share price is 43 cents, down 0.7% today and down 49% over 12 months. 

Since the healthcare sector began its long-awaited rebound on 3 June, Healius shares have soared 29%.

Morgans has a hold rating on this ASX 200 healthcare share following its FY26 report.

The broker said: 

FY26 results were mixed, with revenue and underlying EBITDA broadly in line, but underlying EBIT 5% below consensus and at the bottom of guidance, reflecting still-thin Pathology margins.

Encouragingly, Pathology EBIT margin improved materially in 2H, while labour costs fell 2.9% and group cost growth was contained.

Agilex was again a clear positive, with revenue and earnings growth ahead of expectations.

While FY27 EBIT guidance of A$39.7m is broadly in line with expectations, the T27 target for mid-to-high single-digit EBIT margins was extended by c18 months to Dec-28, leaving us cautious on the pace and sustainability of earnings leverage.

The broker increased its price target to 43 cents, implying the stock is fully valued.

BHP Group Ltd (ASX: BHP)

The BHP share price is $67.93, up 1.2% today and up 57% over 12 months. 

BHP shares reached a new record of $68.22 in earlier trading on Tuesday.

Morgans downgraded BHP shares to a sell call after its FY26 report on 18 August.

The broker explained: 

A solid FY26 result, with an upsized final dividend of US 99cps, against a share price that appears to already factor in more upside, we lower our rating to TRIM.

Metal prices were a key driver, but BHP also maintained a solid operating performance on controllable factors against a tough backdrop in FY26.

The broker reduced its 12-month price target from $59.80 to $55.30.

This suggests a potential 18% downside ahead.

The post Buy, hold, sell: Judo Capital, Healius, BHP shares appeared first on The Motley Fool Australia.

Pleasing FY26 reports from heavyweights CSL Ltd (ASX: CSL) and Pro Medicus Ltd (ASX: PME) turbocharged the sector.

The broader S&P/ASX 200 Index (ASX: XJO) slipped 0.62% over the week to 9,058.9 points on Friday.

Healthcare is in the middle of a rapid recovery following a 29% slump over the 12 months to early June.

The S&P/ASX 200 Health Care Index (ASX: XHJ) reached a 9-year low on 3 June.

The sector then pivoted as value investors rushed in to snap up blue-chips on the cheap.

Healthcare shares have skyrocketed 41% since 3 June, compared to a 3% rise for the ASX 200.

Let's review some specifics from last week.

Healthcare shares led the ASX sectors last week

Last week, several major healthcare companies revealed their latest periodic earnings results.

The CSL share price leapt 23.3% to $168.30 on the strength of its FY26 results last week.

CSL shares have rocketed 82% since the healthcare sector rebound began on 3 June.  

Pro Medicus shares jumped 7.1% to $191.60 on the back of the company's FY26 report.

The Pro Medicus share price is up 20% since 3 June. 

The Cochlear Ltd (ASX: COH) share price rose 1.4% to $135.48 following the hearing implant maker's FY26 report.

Cochlear shares have increased 42% since 3 June.

The Healius Ltd (ASX: HLS) share price jumped 13.8% to 46 cents following its FY26 report last week.

Healius shares are up 38% since 3 June.

The EBOS Group Ltd (ASX: EBO) share price ascended 7.2% to $18.96 following the company's FY26 results.

EBOS shares are up 20% since 3 June.

The Mesoblast Ltd (ASX: MSB) share price lifted 6.8% to $2.36 following a phase 3 trial update.

Mesoblast shares have risen 17% since 3 June.  

ASX 200 market sector snapshot

Here's how the 11 market sectors stacked up last week, according to CommSec data.

Over the five trading days:

The post ASX 200 healthcare shares soar 9% amid notable FY26 reports from CSL, Pro Medicus appeared first on The Motley Fool Australia.

What did Healius Limited report?

• Revenue from continuing operations rose 2.2% to $1,373.2 million (FY25: $1,344.2 million)
• Underlying EBITDA grew 8.1% to $258.6 million
• Underlying EBIT jumped 76.6% to $30.2 million
• Underlying loss after tax improved to $13.2 million from $24.8 million a year ago
• Reported loss after tax widened to $415.6 million, from $151.2 million, due chiefly to a $332 million non-cash goodwill impairment
• No dividend declared for FY26 (FY25: 41.3 cps special dividend)

What else do investors need to know?

Healius delivered operational improvements despite headwinds in the healthcare sector, including increased labour costs and limited Medicare indexation. Cost management helped contain annual spend, aided by a detailed workforce optimisation program reducing headcount by around 5%.

The Agilex Biolabs division performed strongly, growing revenue by 14.1% and EBITDA by over 67%. The company is reviewing strategic options for Agilex Biolabs, and an update for shareholders is expected ahead of the AGM.

Healius completed the major phase of its digital transformation program, with most collection centres now processing over 80% of episodes digitally. AI‑driven initiatives are delivering productivity gains and will continue to be rolled out across back-office and laboratory operations.

What's next for Healius Ltd?

Looking ahead, Healius is focused on expanding higher margin revenue streams in diagnostics, capturing benefits from its completed digital platform rollouts, and further lifting network productivity. The group expects full-year labour cost pressures from regulatory changes, but remains confident about healthcare demand trends over the medium to long term.

The company maintains a strong balance sheet, ending FY26 with net debt of $32.8 million and well within its banking covenants. Management continues to target improved cashflow and margin restoration in FY27.

Healius Ltd share price snapshot

The Healius share price has been sold off over the past 12 months and is down 45%. This compares to a modest 2% gain by the S&P/ASX 200 index (ASX: XJO).

View Original Announcement

The post Healius posts FY26 revenue growth, narrows underlying loss appeared first on The Motley Fool Australia.

That's because I believe it is worth keeping a close eye on short interest levels as high levels can sometimes be a sign that something isn't quite right with a company.

With that in mind, listed below are the 10 most shorted shares on the ASX this week according to ASIC.

The top ten most shorted ASX shares

• DroneShield Ltd (ASX: DRO) has jumped to the top of the table with short interest of 15.1%, which is up again since last week. There are concerns over an ASIC investigation into the counter-drone technology company and increasing competition. 
• 4DMedical Ltd (ASX: 4DX) has seen its short interest ease to 13%. This medical technology company has a sky-high valuation but only recorded revenue of $7.2 million in FY 2026. 
• Domino's Pizza Enterprises Ltd (ASX: DMP) has seen its short interest ease again to 12.4%. Short sellers have been closing positions following an encouraging trading update from the pizza chain operator.
• Boss Energy Ltd (ASX: BOE) has short interest of 12.2%, which is up week on week. This may be due to fears that this uranium miner's production outlook could weaken materially beyond 2027.
• Paladin Energy Ltd (ASX: PDN) has 11.7% of its shares held short, which is down week on week. This uranium producer continues to be targeted despite the release of a positive quarterly update. 
• Flight Centre Travel Group Ltd (ASX: FLT) has 11.6% of its shares held short, which is down week on week. This high level of short interest could be due to fears the Middle East conflict could slow the travel agent's growth. 
• Lotus Resources Ltd (ASX: LOT) has seen its short interest fall materially to 11.6%. Short sellers have closed positions after the uranium developer raised funds at a deep discount. 
• Telix Pharmaceuticals Ltd (ASX: TLX) has seen its short interest ease slightly again week on week to 11.5%. It is possible that short sellers believe the radiopharmaceuticals company could continue to struggle gaining US FDA approvals.
• CAR Group Limited (ASX: CAR) has short interest of 11.5%, which is flat since last week. This auto listings company is releasing its results today. Short sellers appear to believe it could be a poor result.
• Healius Ltd (ASX: HLS) has short interest of 10.7%, which is down slightly week on week. This healthcare company has been battling weaker volumes.

The post These are the 10 most shorted ASX shares appeared first on The Motley Fool Australia.

That's because I believe it is worth keeping a close eye on short interest levels as high levels can sometimes be a sign that something isn't quite right with a company.

With that in mind, listed below are the 10 most shorted shares on the ASX this week according to ASIC.

The top 10 most shorted ASX shares

• Lotus Resources Ltd (ASX: LOT) is still Australia's most shorted share with short interest of 22.5%. This uranium developer's shares returned from their suspension last week and sank deep into the red, much to the delight of short sellers.
• Domino's Pizza Enterprises Ltd (ASX: DMP) has seen its short interest ease to 13.6%. An encouraging trading update from this pizza chain operator last week sent its shares storming higher.
• DroneShield Ltd (ASX: DRO) has short interest of 13.4%, which is up again since last week. Concerns over an ASIC investigation into the counter-drone technology company and increasing competition could be behind this. 
• 4DMedical Ltd (ASX: 4DX) has seen its short interest increasing slightly to 13.4%. This could be due to valuation concerns, with the medical technology company boasting a market capitalisation of around $2.2 billion but revenue of $7.2 million in FY 2026.
• Flight Centre Travel Group Ltd (ASX: FLT) has 12.2% of its shares held short, which is up week on week again. There may be concerns that the Middle East conflict could negatively impact the travel agent's booking volumes. 
• Paladin Energy Ltd (ASX: PDN) has 12% of its shares held short, which is up week on week. Short sellers are not giving up on this uranium producer despite the release of a positive quarterly update.
• Telix Pharmaceuticals Ltd (ASX: TLX) has seen its short interest ease slightly week on week to 11.7%. It hasn't been as easy as expected for this radiopharmaceuticals company to gain US FDA approvals over the past 18 months.
• Boss Energy Ltd (ASX: BOE) has short interest of 11.6%, which is down week on week. There are concerns over this uranium miner's production outlook beyond 2027.
• CAR Group Limited (ASX: CAR) has short interest of 11.5%, which is down since last week. This may be due to fears that higher interest rates could negatively impact auto listings.
• Healius Ltd (ASX: HLS) has entered the top ten with short interest of 10.8%. This healthcare company has been battling weaker volumes. Short sellers don't appear to believe this trend will change in the near term.

The post Which are the 10 most shorted ASX shares? appeared first on The Motley Fool Australia.

Let's check out some new ratings on three ASX shares.

Southern Cross Gold Consolidated Ltd (ASX: SX2)

This ASX gold share closed at $9.50, down 4.4% yesterday.

The Southern Cross Gold share price has risen by more than 60% over 12 months.

Shaw and Partners has a buy rating on the gold explorer. 

The broker gives Southern Cross Gold shares a 12-month price target of $14.40 based on a discounted cash flow (DCF) valuation.

Analyst Alex Barkley said:

Our base case forecasts support our Buy Recommendation, with an implied ~40% stock upside.

We also find substantial project upside potential at Sunday Creek.

Geological extension potential could extend mine life or importantly, allow a larger mining capacity.

Any project expansion returns could be supercharged by the remarkable ~9g/t AuEq site grade.

Key upcoming catalysts include ongoing drilling, an Exploration Target update in Q2 CY26, and a maiden Resource in Q1 CY27. 

Centuria Office REIT (ASX: COF)

Centuria Office REIT shares closed steady at 91 cents yesterday.

The ASX real estate investment trust (REIT) has fallen 27% over 12 months.

Bell Potter recently maintained its hold call on this ASX property share and lowered its target from $1.05 to 95 cents.

Analyst Michael Armstrong said:

COF is facing headwinds to earnings from tricky conditions in key exposed markets, rising interest rates, and dilutionary asset divestments.

We forecast earnings declining in FY27 (-2.7% below consensus), holding in FY28, before returning to growth in FY29.

COF screens inexpensive on a P/E and NTA basis but is trading at a P/E to Growth (PEG) ratio of 13.0x, placing it well above peers (sector simple avg. 2.9x).

We see better risk-adjusted opportunities in other sub-sectors at present and believe a pickup in the suburban market is still a little way off.

Healius Ltd (ASX: HLS)

This ASX healthcare share closed steady at 35 cents on Thursday.

The Healius share price has tanked 62% over 12 months.

After the company issued an FY26 earnings downgrade, Jarden kept its sell rating in place.

The broker has a price target of 47 cents, which implies 34% capital growth ahead.

The post Buy, hold, sell: Southern Cross Gold, Healius, Centuria Office REIT shares appeared first on The Motley Fool Australia.

Brokers have reduced their ratings on several stocks this week.

Let's take a look.

CSL Ltd (ASX: CSL)

The CSL share price is $97.98, up 0.7% today.

Over the past month, this ASX 200 healthcare share has fallen another 30%.

Jarden downgraded CSL shares from a buy to hold rating on Tuesday.

The broker slashed its 12-month price target from $244 to $191.

This still suggests major potential upside of 95% over the next 12 months.

GrainCorp Ltd (ASX: GNC)

The Graincorp share price is $5.23, down 2.9% and down 20% over the past month.

Morgans downgraded this ASX 200 agribusiness share after the company released its 1H FY26 results.

The broker moved to a hold rating with a $5.62 target, implying 7.5% upside ahead.

In a note, the broker said:

GNC's 1H26 result was weak but broadly in line with consensus at the NPAT level. Business unit performance was stronger for Agribusiness but materially weaker for Nutrition & Energy given a one-off derivate timing issue.

GNC reported a significantly larger than expected cash outflow and its core cash position was also lower than expected.

The era of special dividends now appears to be over. GNC reiterated its FY26 earnings guidance. 

Looking ahead to FY27, Morgans said dry El Nino conditions and cost pressures would likely lead to a "much smaller crop".

GNC's strategic assets are worth materially more than its current share price.

However, given earnings look set to decline again in FY27, the stock is lacking share price catalysts, and we move to a HOLD recommendation.

Healius Ltd (ASX: HLS)

The Healius share price is 37 cents, down 1.4% on Friday.

Over the past five trading days, this ASX healthcare stock has fallen 27%.

Healius shares were smashed after the company issued an FY26 earnings downgrade.

RBC Capital downgraded Healius shares to a sell rating this week.

The broker slashed its 12-month price target from 75 cents to 35 cents.

This indicates the stock is fully priced.

Amotiv Ltd (ASX: AOV)

The Amotiv share price is $6.25, up 0.2% today.

Over the past six months, this ASX consumer discretionary share has fallen 30%.

Citi downgraded Amotiv shares to a hold rating on Tuesday.

The broker slashed its price target from $9.30 to $6.70, indicating limited upside ahead.

Mach7 Technologies Ltd (ASX: M7T)

The Mach7 Technologies share price is 28 cents, up 1.8% today.

In the calendar year to date, this ASX healthcare share has tumbled 59%.

Canaccord Genuity downgraded Mach7 shares to a hold rating with a 27-cent target on Tuesday.

This suggests the stock is fully priced.

The post 5 ASX shares downgraded by brokers this week appeared first on The Motley Fool Australia.

Does the broker rate them as buys, holds, or sells? Let's dig deeper into things:

Aristocrat Leisure Ltd (ASX: ALL)

Morgans was impressed with this gaming technology company's performance in the first half of FY 2026. It notes that Aristocrat outperformed expectations thanks largely to its gaming business.

In response, the broker has retained its buy rating on Aristocrat shares with an improved price target of $67.00. It said:

Aristocrat Leisure (ALL) 1H26 result beat our forecasts and came broadly in line with consensus, despite management's prior flagging of a softer than usual 1H skew. Gaming was the clear standout – strong outright sales on continued Baron cabinet demand and solid leased adds in a thin content period. Product Madness and Interactive came in below our forecasts, though the latter is complicated by a D&D reclassification and acquisition drag that flatters the headline miss.

Greater clarity on the FY26-29F earnings shape is expected at the July investor day. Capital management remains a key pillar – a $1bn buyback extension marks $5.1bn returned over five years, underpinned by a fortress balance sheet at 0.3x net debt/EBITDA. We now assume a normalised 1H/2H skew and incorporate ~$100m in annualised savings in FY27, lifting EPSA 3% and 4% for FY26-27F respectively.

Breville Group Ltd (ASX: BRG)

Another ASX share that Morgans is positive on is appliance manufacturer Breville.

Following the release of positive updates from peers, the broker has retained its buy rating on Breville's shares with a $36.75 price target. It commented:

1Q26 updates from key offshore peers have shown broadly positive read-throughs for BRG, despite an ongoing challenging consumer and macro backdrop. We consider small domestic appliance peers with a premiumisation focus (DLG / KitchenAid), innovation-led NPD (SN), high Coffee exposure (DLG) and ongoing geographic expansion (all) as holding strong relevance for BRG.

Sales momentum across these select peers in 1Q26 (DLG +6.6%; Ninja brand +9.1%; KitchenAid +10%) appears broadly positive and supportive of our view for ongoing outperformance from BRG. BUY maintained.

Healius Ltd (ASX: HLS)

Finally, Morgans was disappointed with this healthcare company's update and sizeable downgrade to earnings.

And given the increased uncertainty over the outlook of its pathology business, the broker has retained its hold rating with a reduced price target of 41 cents. It said:

HLS has materially downgraded FY26 earnings, which we find disappointing given reiterated consensus-aligned guidance at the 1H26 result only three months ago. While Pathology cost control continues to improve and labour optimisation initiatives are gaining traction, weaker volumes, ongoing GP softness and mounting regulatory/funding pressures are offsetting operational progress. Agilex continues to perform relatively well, and HLS has commenced a strategic review following unsolicited interest in the asset.

However, the extent to which value can be crystallised above the original high acquisition multiple remains uncertain given the business' modest scale and inconsistent earnings trajectory. While a potential Agilex sale could provide balance sheet upside, the downgrade reinforces that sustainable margin recovery within core Pathology remains elusive. We adjust FY26-28 estimates, with our target price decreasing to A$0.41. HOLD.

The post Buy, hold, sell: Aristocrat, Breville, and Healius shares appeared first on The Motley Fool Australia.

In afternoon trade, the ASX 300 share is down 23% to a multi-year low of 37.2 cents.

Why is this ASX 300 share crashing today?

The selling has been sparked by the release of a trading update for FY 2026, which points to a challenging operating environment for the pathology company.

According to the release, Healius now expects group underlying EBITDA of between $259 million and $264 million for FY 2026. It also expects group underlying EBIT of between $30 million and $35 million.

This compares positively to underlying EBITDA of $239.3 million and underlying EBIT of $17.1 million in FY 2025.

Pathology pressures continue

However, taking some of the shine off the profit update was an update on trading conditions.

Management advised that there is ongoing pressure in Healius' pathology business.

For the first half, pathology volumes grew by 1.2% and revenue increased by 3.5%. However, momentum appears to have weakened since then.

For the 10 months to April 2026, pathology volumes declined by 0.4%, while revenue growth slowed to 2.4%.

This is a concern because the division remains the company's core business.

GP attendances have also been soft, falling 1.5% in the first half and 1.0% for the January to March period.

Wage costs add another headwind

Healius has been working to contain costs, with pathology costs rising just 1.1% for the 10 months to April 2026.

However, wage pressure is now emerging as a fresh challenge.

The company advised that pathology labour costs will be impacted by $1.8 million in the fourth quarter due to the Fair Work Commission's initial findings on gender-based undervaluation.

Pathology collectors received an increase from 1 April 2026, with further increases still to come.

Healius said pathology labour costs have now increased 0.8% for the 10 months to April 2026, whereas previous guidance had been for broadly flat labour costs for FY 2026.

The company is now undertaking a strategic review of its Agilex Biolabs and could consider selling the business.

Federal Budget disappointment

Another negative in the update was Healius' response to the Federal Budget.

The ASX 300 share said this year's Federal Budget contained no new funding for pathology, despite the sector facing rising wage costs and an ongoing indexation freeze for most tests.

Management warned that inadequate funding has forced difficult decisions, including cutting staff, closing collection centres, and closing regional laboratories.

The company also said out-of-pocket fees for pathology tests may be the only viable option left to bridge the funding gap.

Overall, today's update highlights a difficult mix of slowing pathology volumes, rising wage costs, limited government funding support, and pressure on earnings.

That combination appears to have spooked investors and sent the ASX 300 share sharply lower.

The post Why is this ASX 300 share crashing over 20% today? appeared first on The Motley Fool Australia.

Four ASX shares that are falling more than most today are listed below. Here's why they are dropping:

Commonwealth Bank of Australia (ASX: CBA)

The CBA share price is down 10% to $154.64. This follows the release of the big four bank's third-quarter update this morning. CBA revealed that its operating income was flat on the first-half quarterly average, with higher net interest income offset by lower other operating income. Cash profit was down 1% on the first-half quarterly average. This was softer growth than the market was expecting. However, the federal budget overnight also appears to have impacted sentiment and could be adding further pressure to CBA shares on Wednesday. The team at Morgan Stanley has warned that the budget creates more downside risk for bank earnings multiples.

Healius Ltd (ASX: HLS)

The Healius share price is down 21% to 38.2 cents. This morning, the pathology company released a trading update and revealed that it expected to report EBIT of $30 million to $35 million in FY 2026. The company also spoke critically about the federal budget, highlighting that inadequate funding is causing challenges. It said: "Last night's Federal Budget contains no new funding for pathology, a sector already operating under an indexation freeze for most tests. […] Inadequate funding has resulted in difficult decisions to cut staff, close collection centres and regional laboratories. This year's Federal Budget will put additional pressure on a sector which is a critical part of Australia's primary healthcare system."

Paladin Energy Ltd (ASX: PDN)

The Paladin Energy share price is down 11% to $11.29. This follows the release of a trading update from the uranium producer this morning. Paladin Energy posted a 51% increase in revenue to US$209.1 million for the nine months. However, its net profit after tax was only US$1.7 million. It also recorded an operating cash outflow of US$36.4 million. Investors appear to have been expecting stronger financial results for the nine months.

Temple & Webster Group Ltd (ASX: TPW)

The Temple & Webster share price is down 4% to $5.10. This morning, the online furniture retailer revealed that FY 2026 revenue is expected to be in the range of $665 million to $675 million. This will be an increase of 11% to 12% on the prior corresponding period. Temple & Webster's EBITDA is expected to be in the range of $20 million to $22 million. This will be an increase of 6% to 17% over the prior corresponding period. Temple & Webster's outgoing founder and CEO, Mark Coulter, said: "We remain firmly focused on growing our market share and reaching $1 billion in revenue by FY28, and becoming a larger, more profitable business. However right now, given the uncertainty in the Australian economy, we have prudently chosen to rebalance between profit and growth in our core business."

The post Why CBA, Healius, Paladin Energy, and Temple & Webster shares are sinking today appeared first on The Motley Fool Australia.

ASX 200 shares soared 2.6% to an intraday peak of 8,804 points in morning trading on Tuesday.

Leading the market today are Guzman Y Gomez Ltd (ASX: GYG) shares, up 18%, and Nextdc Ltd (ASX: NXT), up 12%.

However, some ASX shares are bucking the trend.

Here are six stocks that hit 52-week lows today.

Sonic Healthcare Ltd (ASX: SHL)

Sonic Healthcare is one of several ASX healthcare shares trading at multi-year lows these days.

The sector faces multiple headwinds, including currency changes, US tariffs, and higher labour costs and other expenses.

The Sonic Healthcare share price fell to a decade-low of $18.88 today.

This ASX healthcare share has fallen 13% in the year to date (YTD) and 21% over the past year.

Ord Minnett has a hold rating on Sonic Healthcare with a 12-month share price target of $24.

Stockland Corp Ltd (ASX: SGP)

The Stockland share price fell to a 52-week low of $4.01 today.

Stockland shares are down 30% YTD.

In a separate article, my colleague Aaron has delved into the reasons this ASX property share has tanked in 2026.

Macquarie has just reiterated its buy rating on Stockland shares with a target price of $4.42.

Endeavour Group Ltd (ASX: EDV)

The Endeavour share price fell to a record low of $3.13 on Tuesday.

Endeavour shares have tumbled 14% YTD.

Citi recently downgraded this ASX consumer staples share to a hold rating.

The broker reduced its 12-month target from $4.30 to $3.70.

Atlas Arteria Group Ltd (ASX: ALX)

The Atlas Arteria share price fell to a nine-year low of $4.21 today.

Shares in the toll roads operator have fallen 13% YTD.

Last week, Morgan Stanley maintained its hold rating on Atlas Arteria shares.

The broker reduced its share price target from $5.06 to $4.96.

Lendlease Group (ASX: LLC)

The Lendlease share price dropped to an all-time low of $3.10 on Tuesday.

The ASX real estate share has fallen 39% in 2026.

Today, Macquarie reiterated its buy rating with a 12-month price target of $4.99.

Healius Ltd (ASX: HLS)

The Healius share price dropped to a record low of 51 cents today.

The ASX healthcare share has declined 43% YTD.

Goldman Sachs reiterated its sell rating on Healius shares last month.

The broker lowered its price target from 66 cents to 57 cents.

The post 6 ASX shares hitting 52-week lows amid today's market rally appeared first on The Motley Fool Australia.

Today, 307 ASX shares are rising, 48 are steady, and 145 are falling.

Among the fallers are these four companies that have hit 52-week low share prices today.

Are they a buy, hold, or sell?

Let's ask the experts.

Fletcher Building Ltd (ASX: FBU)

The Fletcher Building share price fell to a 52-week low of $2.42 on Tuesday.

This ASX industrials share is down 21% in the year to date (YTD), and down 17% over the past 12 months.

On The Bull this week, Blake Halligan from Catapult Wealth revealed a sell rating on the building materials and services provider.

He said the 1H FY26 report "highlighted ongoing pressure", with net debt remaining elevated and the company cutting capital expenditure.

Halligan said:

Earnings before interest and tax from continuing operations before significant items was $NZ145 million, which was marginally below expectations. The company has announced the sale of its construction division for $NZ315.6 million.

However, broader conditions in New Zealand remain subdued, and a meaningful earnings recovery isn't expected until calendar year 2027. With limited catalysts and no dividend support, better opportunities present elsewhere.

Guzman Y Gomez Ltd (ASX: GYG) 

The Guzman Y Gomez share price sank to a record low of $15.48 in earlier trading.

The ASX consumer discretionary share has fallen 26% YTD and tumbled 50% over 12 months.

Morgans has a buy rating on the stock but recently slashed its 12-month price target from $32.30 to $24.

The broker said:

If it was just about Australia, GYG would be doing just fine right now. But it's not just about Australia.

Unfortunately, the pace of network expansion in the US so far has been pedestrian and the restaurants it has opened have lost more money than expected.

GYG has a bit to prove, but we can be certain it is going to give it all it's got to ultimately realise its growth ambitions.

Endeavour Group Ltd (ASX: EDV)

The Endeavour share price fell to a record low of $3.28 today.

Endeavour shares have declined 10% YTD and have fallen 14% over the past 12 months.

Last week, Citi downgraded the ASX consumer staples share to a hold rating.

The broker also reduced its 12-month price target from $4.30 to $3.70.

Healius Ltd (ASX: HLS)

The Healius share price dropped to a record low of 52 cents today.

This ASX healthcare share has crashed 42% in the YTD and 63% over 12 months.

Healius is one of many ASX healthcare shares trading at multi-year lows today.

The sector is facing multiple headwinds due to currency shifts, US tariffs, and higher labour costs and other expenses.

Healius, a pathology services provider, reported improved financial metrics but continuing losses overall in its 1H FY26 report.

The company reported an underlying loss of $11 million for 1H FY26, which was an improvement on its $20.2 million loss for 1H FY25.

Morgans has a hold rating on Healius shares with a 12-month target of 80 cents.

The broker commented:

While management maintained FY26 earnings in line with consensus and operational discipline is improving, sustainable earnings leverage remains an open question and dependent on execution.

The post 4 ASX shares at 52-week lows: Buy, hold, or sell? appeared first on The Motley Fool Australia.

The ASX All Ords hit an all-time high of 9,436.2 points on Friday, the final day of earnings season, and fell 0.13% yesterday.

Today, the market is substantially lower as investors continue to weigh how the US and Israel attack on Iran will affect world order.

Energy is the only sector in the green today as oil and gas prices continue to climb on expectations of disrupted global supply.

Meanwhile, three ASX All Ords shares have hit 52-week lows today.

Are they a buying opportunity, or is it best to steer clear?

Let's defer to the experts.

4 ASX All Ords shares slumping to 52-week lows

HMC Capital Ltd (ASX: HMC)

This ASX All Ords financial share fell to a 52-week low of $2.54 on Tuesday.

That's a 72% deterioration over 12 months, but Morgans sees the upside.

The broker retained its buy rating on HMC Capital shares after reviewing the company's 1H FY26 report.

In a note, Morgans commented:

We still see value in HMC, with our market-to-market NTA at c.$2.30 per share, or c.$3.00 when we factor in our valuation for the listed co-investments (HDN, HCW, DGT), while the c.$60m of recurring funds management EBITDA adds additional value.

Morgans lowered its 12-month price target from $4.85 to $4.45.

Healius Ltd (ASX: HLS)

The Healius share price tumbled to a 52-week trough of 66 cents today.

This ASX All Ords healthcare share has halved in value over the past 12 months.

Morgans reiterated its hold rating after reviewing the pathology services provider's 1H FY26 report.

The broker commented:

While management maintained FY26 earnings in line with consensus and operational discipline is improving, sustainable earnings leverage remains an open question and dependent on execution.

The broker gives the ASX All Ords healthcare share a 12-month target of 80 cents.

DigiCo Infrastructure REIT (ASX: DGT)

This ASX All Ords real estate investment trust (REIT) fell to a 52-week low of $1.93 on Tuesday.

The data centre specialist has lost more than 55% of its value over the past year.

Morgans is optimistic, however, after going over the company's 1H FY26 results.

The broker commented:

DGT continues to trade at a c.50% discount to NAV of A$4.62/security, yet that NAV does not yet reflect the full value of the 88MW SYD1 expansion, which management estimates will deliver a further c.A$1.50/security of NAV uplift at a targeted 15% yield on cost.

Acknowledging the share price weakness, we continue to see the opportunity in DGT, retaining our Buy rating with a $4.15/sh price target.

Beacon Lighting Group Ltd (ASX: BLX)

This ASX All Ords consumer discretionary share reached a 52-week low of $2.02 today.

That's a 41% fall over 12 months.

However, Morgans upgraded Beacon Lighting from accumulate to buy on the back of its 1H FY26 report.

The broker commented:

BLX 1H26 result was weaker than expected, driven by softer sales in both retail and trade, which has tempered expectations of a meaningful recovery in the 2H.

Whilst earnings recovery is likely longer dated, we see long-term opportunity in trade, store network growth, and margin expansion as the cycle turns.

The broker lowered its share price target from $3.80 to $3.20.

The post 4 ASX All Ords shares at 52-week lows. Should you buy? appeared first on The Motley Fool Australia.

Healius shares are down 2.45% today to 71.7 cents.

That follows a 6.75% fall on results day and a further 3.29% decline in the prior session. The stock is now trading at a record low and is down around 20% since the start of 2026.

While parts of the business showed improvement, investors remain focused on the company's ongoing losses.

Let's take a closer look at what was reported.

Revenue rises but losses remain

For the 6 months to 31 December 2025, Healius reported revenue of $688.1 million, up 3.8% on the prior corresponding period.

Underlying EBITDA increased 13.1% to $122.2 million. The company also delivered underlying EBIT of $7.9 million, an improvement on the loss recorded a year earlier.

The core pathology division generated revenue of $666.3 million, up 3.5%, with EBIT improving to $5.2 million.

Agillex Biolabs, which provides specialist laboratory services to pharmaceutical and biotechnology companies, was a stronger performer. Revenue increased 16% to $21.8 million, and EBIT rose 145.5% to $2.7 million.

Despite these improvements, Healius reported a statutory net loss after tax of $30.4 million, reflecting restructuring costs, digital program expenses, and finance costs.

The company also confirmed it will not pay an interim dividend.

Balance sheet and cost savings in focus

Healius ended the half with net cash of $11.6 million. It held $51.6 million in cash and had $40 million in drawn debt.

Management said cost reduction initiatives are continuing. The company is targeting $15 million to $20 million in annual support cost savings, with $10.7 million in annualised savings already delivered in the first half.

The group also confirmed its major digital program has been completed, with future technology spend expected to return to more typical levels.

Healius expects full-year earnings to be in line with current market expectations and continues to target high single-digit EBIT margins by June 2027.

Investors remain unconvinced

Although some operating metrics improved, the market is focused on the continued statutory loss and the uncertainty around the pace of recovery.

With the share price now at a record low, investor confidence remains weak. The market is looking for clearer evidence that revenue growth and cost reductions can deliver consistent profits.

Foolish Takeaway

Healius is delivering some improvement at an operational level, particularly in pathology and Agillex. However, the company remains loss-making on a statutory basis and is not returning cash to shareholders.

Until profits stabilise and become consistent, the share price may remain under pressure despite signs of progress.

The post Healius shares hit record low after half-year loss. Here's what happened appeared first on The Motley Fool Australia.

Four ASX shares that have failed to follow the market higher today are listed below. Here's why they are falling:

Baby Bunting Group Ltd (ASX: BBN)

The Baby Bunting share price is down 3.5% to $2.30. This morning, analysts at Morgans reaffirmed their hold rating on this baby products retailer's shares with a trimmed price target of $2.60. The broker said: "BBN's 1H26 pro-forma NPAT was up 4.1% yoy to $5.0m which was in the middle of guidance range ($4.5-$5.5m) driven by comps sales growth, gross margin expansion offset by higher costs. Nine stores have been refurbished to the new store design, and have performed strongly, sales up 25%, which is at the upper end of guidance range of 15-25%. FY26 NPAT guidance has been narrowed to $17.5-$19.5m (was $17-20m). We have made minor changes to forecasts. We have a $2.60 target price (was $2.70) Hold recommendation retained."

Capstone Copper Corp (ASX: CSC)

The Capstone Copper share price is down 18% to $12.78. This follows the release of the copper miner's guidance for 2026. Capstone Copper expects consolidated copper production of between 200,000 and 230,000 tonnes in 2026. This is broadly in line with 2025 levels. Management also advised that it expects consolidated C1 cash costs of US$2.45 to US$2.75 per payable pound of copper in 2026. This is an increase compared to 2025, primarily due to modest inflation and lower-grade ore at Mantos Blancos and Pinto Valley driven by mine sequencing.

Healius Ltd (ASX: HLS)

The Healius share price is down 11% to 72.7 cents. This morning, this healthcare company released its half-year results and reported a 3.8% increase in group revenue to $688.1 million and underlying EBIT of $7.9 million. The latter was up from a loss of $2.7 million a year ago. While management expects to achieve earnings in line with consensus estimates in FY 2026, it warned that its revenue and profitability will be skewed towards the second half. This is due to both the timing of cost savings and normal volume seasonality factors. The market appears sceptical that it will deliver on this guidance.

Suncorp Group Ltd (ASX: SUN)

The Suncorp share price is down 5% to $15.19. Investors have been selling this insurance giant's shares following the release of its half-year results. Suncorp reported a net profit after tax of $263 million, which is down heavily from $1.1 billion a year earlier. The company's CEO, Steve Johnston, said: "While Suncorp's 1H26 reported profits and shareholder returns have been challenged by an elevated level of natural hazard costs and lower investment returns over the half, our underlying business remains resilient as we continue to deliver on our strategic imperatives and drive good momentum leading into the second half of the financial year."

The post Why Baby Bunting, Capstone Copper, Healius, and Suncorp shares are falling today appeared first on The Motley Fool Australia.

What did Argo Investments Limited report?

• Half-year profit: $130.8 million, up from $121.2 million last year
• Earnings per share: 17.2 cents, up from 15.9 cents
• Interim dividend: 18.5 cents per share (fully franked), up 8.8%
• Management expense ratio: 0.14%, improved from 0.15%
• Grossed-up annual yield: 6.1% based on the last closing share price

What else do investors need to know?

Argo's investment revenue from its portfolio was flat over the half, but profit was lifted by trading and options income. The company has boosted its fully franked dividend by 37.5% over the past five years, maintaining 100% franking even throughout volatile market conditions.

During the period, Argo made some notable investment changes, adding CSL Ltd (ASX: CSL), Amcor (ASX: AMC), Worley Ltd (ASX: WOR), Rio Tinto Ltd (ASX: RIO), BHP Group Ltd (ASX: BHP) , Generation Development Group Ltd (ASX: GDG), and Clarity Pharmaceuticals Ltd (ASX: CU6), while selling all shares in Healius Ltd (ASX: HLS) and GPT Group (ASX: GPT). The total number of portfolio stocks decreased slightly from 85 to 83.

What did Argo Investments management say?

Managing Director Jason Beddow said:

We considered it appropriate to meaningfully increase the interim dividend. The Board is committed to sustainably growing Argo's fully franked dividends.

What's next for Argo Investments?

Looking ahead, Argo noted the outlook remains highly uncertain given ongoing geopolitical risks and shifting monetary policy, including higher Australian interest rates. The team highlighted Australia's structural advantages, particularly in resources and critical minerals.

Argo plans to keep its diversified approach, spanning more than 80 ASX-listed companies. The company says it aims to provide shareholders with reliable income and long-term capital growth, even through volatile markets.

Argo Investments share price snapshot

Over the past 12 months, Argo Investments shares have risen 1%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 3% over the same period.

View Original Announcement

The post Argo Investments reports record profit and dividend appeared first on The Motley Fool Australia.

Will the market be able to bounce back from this on Thursday? Here are five things to watch:

ASX 200 expected to fall again

The Australian share market looks set to fall again on Thursday following a mixed night on Wall Street. According to the latest SPI futures, the ASX 200 is expected to open the day 40 points or 0.45% lower this morning. In late trade in the United States, the Dow Jones is down 0.2%, the S&P 500 is flat, and the Nasdaq is up 0.55%.

Oil prices rise

ASX 200 energy shares Beach Energy Ltd (ASX: BPT) and Santos Ltd (ASX: STO) could have a decent session on Thursday after oil prices pushed higher overnight. According to Bloomberg, the WTI crude oil price is up 0.3% to US$60.33 a barrel and the Brent crude oil price is up 0.6% to US$64.79 a barrel. A large decline in US stockpiles was behind this rise.

Annual general meetings

A number of ASX 200 shares are holding their annual general meetings today and could provide the market with trading updates. Among the companies holding events are corporate travel specialist Corporate Travel Management Ltd (ASX: CTD), healthcare company Healius Ltd (ASX: HLS). Retail giant JB Hi-Fi Ltd (ASX: JBH), and Bunning and Kmart owner Wesfarmers Ltd (ASX: WES).

Gold price fall

It could be a poor session for ASX 200 gold shares Newmont Corporation (ASX: NEM) and Northern Star Resources Ltd (ASX: NST) on Thursday after the gold price tumbled into the red. According to CNBC, the gold futures price is down 0.75% to US$3,952.3 an ounce. Traders were selling gold after the US Federal Reserve cast doubts on a December rate cut.

Buy Woolworths shares

Now could be the time to buy Woolworths Group Ltd (ASX: WOW) shares according to analysts at Bell Potter. This morning, the broker has upgraded the supermarket giant's shares to a buy rating with a $30.70 price target. It said: "We upgrade from Hold to Buy. WOW has been in an earnings downgrade cycle for two years and this looks to be coming to an end. Trading at a reasonable ~12% discount to COL and ~14% discount to its historical FWD EV/EBITDA, there is now a reasonable valuation arbitrage, just as the underperformance in Australian Food looks to be bottoming and out-of-home indicators improving (the latter a positive for B2B)."

The post 5 things to watch on the ASX 200 on Thursday appeared first on The Motley Fool Australia.